Myeloma-Developing Regimens Using Genomics (MyDRUG) (Genomics Guided Multi-arm Trial of Targeted Agents Alone or in Combination With a Backbone Regimen)
Latest Information Update: 20 Feb 2025
At a glance
- Drugs Abemaciclib (Primary) ; Belantamab mafodotin (Primary) ; Cobimetinib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Enasidenib (Primary) ; Erdafitinib (Primary) ; Ixazomib (Primary) ; Pomalidomide (Primary) ; Selinexor (Primary) ; Venetoclax (Primary)
- Indications Multiple myeloma
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms MyDRUG
Most Recent Events
- 14 Feb 2025 Status changed from recruiting to completed.
- 25 Sep 2024 According to a Multiple Myeloma Research Foundation Media Release, new data in oral and poster presentation to be shared at the 21st International Myeloma Society (IMS) Annual Meeting, being held in Rio De Janeiro, Brazil, September 25-28, 2024.
- 12 Dec 2023 Results (n=17) reporting safety and efficacy data of sub-protocol Y3 arm of this trial presented at the 65th American Society of Hematology Annual Meeting and Exposition